Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the high short interest stocks to buy right now. On November 21, H.C.

Madrigal Pharmaceuticals is relocating to a larger West Conshy headquarters as sales surge and its MASH treatment drives ...

Since its launch, Rezdiffra has made steady commercial progress. In the third quarter, Madrigal's single approved product ...

MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic ...

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...

Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Investing.com -- Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) stock gained 3.7% on Thursday after the company announced it received a new patent in South Korea for its lead compound Aramchol in ...

Nicotine addiction remains one of the most persistent global health challenges, yet the cellular mechanisms underlying it are less explored. Now, researchers have discovered that astrocytes, glial ...

Caris Life Sciences® , a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading cancer centers, ...

Previously, Galmed announced the grant of new use patent for a combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH. The new patent extends Aramchol's patent ...

Resmetirom effectively resolves MASH and improves fibrosis, independent of GLP-1 or SGLT2 inhibitor use, in patients with T2DM. Achieving ≥5% weight loss enhances resmetirom's effects on MASH ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Resmetirom maintained meaningful improvements in MASH ...